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ABSTRACT
Systematic review is a method to combine multiple sources of evidence through an explicit and reproducible way of
literature search and critical appraisal of the quality of included studies, with or without mathematical methods to
synthesis these information. Since this method was first introduced more than centuries ago, systematic review has
been increasingly popular and widely used particularly in the area of medicine. Systematic review is often very
useful to physicians to help supporting the clinical decision making and significantly reducing their time to seek for
appropriate evidence. However, despite its reproducible and systematic steps to substantially minimize the presence
of biases, physicians should still be aware that systematic review is not completely biases resistant. Inclusion of
poor quality studies, heterogeneity, and publication or other reporting biases are commonly evident in systematic
review that may hinder the quality of the conclusion. This review summarizes the core principals of systematic
review and its potential biases, and discusses when the systematic review is useful or needing careful attention.
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INTRODUCTION
Clinical decision making can be easy but
sometimes is also complicated. Physicians often
experienceaproblematicclinicaldecisionmakingwhen
there are multiple sources of information for example
from primary data, patient’s preferences, individual’s
experience, hospital policy, and enormous amount of
scientific evidence. This may become worse if sources
of information to be drawn is conflicting rather than
yielding similar conclusion. For example, few recent
trials suggest the benefit of lipid-lowering drugs for
patients with diabetes in addition to standard glucose
control therapy to prevent the development of
microvascular complications.1,2 On the contrary, at the
same time, there is strong evidenceshowing that serum
lipids are not consistently associated with diabetic
microvascular complications.3 So which ones should
physicians rely on?
An approach to put together this information into
asinglereviewarticleisincreasingly important inclinical
setting. Unfortunately, since reviewing is a very
subjectiveprocessanddependsmuchon the reviewer’s
capacity to review, perform literature search, absorb
information, and generate the conclusion, medical
review article is often scientifically inaccurate and less
reliable for decision making. Therefore, there is a need
for a clear strategy for literature identification and
selection, systematic assessment of the quality of
evidence, and coherent and instructive way of
synthesizing data into a concise and unified piece of
information more applicable to clinical practice, the
so-called systematic review.
In the last decade, systematic review articles
including, if appropriate, meta-analysis are becoming
popular and notably the ground for decision making in
many clinical settings. More importantly, thecredit that
has been given to systematic review as “the best
scientific evidence” is of great interest for practicing
physicians who demand representative “synoptic”
evidence that helps reducing their trivial time to select
and read primary reports.4 Nevertheless, not many of
theseempiricism-drivenphysicians realizethatcautious
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interpretations of systematic review should still be
made. First, because not only the fact that there are
still a few caveats of systematic review that should be
taken into consideration (e.g publication bias,
heterogeneity), but second, there has also been
evidence lately showing the limitations and abuses of
systematic review.5 This paper summarizes the core
concepts of systematic review including its historical
perspectives, principals and applications, and pitfalls
in the context of clinical practice.
Historical perspectives
In the 17 th century, astronomy and geodesy
institution suggested the use of combination of data
rather than single data to obtain a better and more
representative result,6 which was perhaps the statistical
embryo of meta-analysis. In the area of medicine, the
idea of compiling and summarizing relevant evidence
for physicians began in the 18th century, in response
to the need of busy physicians for relevant research
information.7 Two German- and English-written
journals published in Leipzig, Germany (Commentarii
de Rebus in Scientia Naturali et Medicina Gestis,
1752 – 1798) and in Edinburgh (Medical and
Philosophical Commentaries, 1773 – 1780) reported
abstractsofarticles andnewimportantbookspublished
elsewhere, for example including the book on the use
of digitalis for heart disease treatment (Account of
foxglove, 1785).7 It was Andrew Duncan Sr. (1744 –
1828), the “anonymous” editor of Medical and
Philosophical Commentaries, who amongst the first
to critically appraise the medical practice in late 18th
century in Britain. One century later, in 1904, Karl
Pearson, for the first time, introduced the formal
statistical techniques to combine data from different
studies.8 He proposed that many data are just too small
considering the possibility of error, thus insufficient to
obtain strong and generalizable conclusion, which
remains the basis of systematic review/ meta-analysis
these days.
In the following years, this technique was barely
used in medicine. On thecontrary, researchers in social
science and education showed an early interest in the
synthesis of research findings.9 In 1950s, David
Sackett, a clinical epidemiologist at McMaster
University, Ontario, Canada, and others developed the
conceptof“criticalappraisal”of researchreports,which
has been one of the most substantial components of
systematic review,10 but the term “meta-analysis” was
first mentioned in the paper by a psychologist in 1976,
titled “Primary, secondary, and meta-analysis of
research”.11Within less than5subsequentyears,British
physicians and epidemiologist, Archie Cochrane,
becameaware that therewere, in fact, many physicians
without proper access to reliable evidence to support
their clinical practice. Thiswas theprimary foundation
of thought to establish the CochraneCollaboration that
facilitateswideaccess in systematic reviews in the later
decades.12 Systematic review and meta-analysis in
medicine havebecome very popular particularly in the
fields of cardiovascular diseases and oncology since
1980s.13
The need for systematic review: limitation of a
single study and narrative (non-systematic)
review
In an article by Freiman and associates published
in the New England Journal of Medicine in 1978,14
seventy-oneclinical trial reportswereassessed whether
they had sufficient power (>90%) to detect 25% and
50% difference in treatment effect. Surprisingly, most
ofthesetrialsreportednegativefindingsbut interestingly,
57 of these negative trials had 25% potential
improvement to show the significant treatment effect.
This tells that single study often fails to achieve the
required sample size to detect an association. Such
study may therefore produce false negative results by
showing no significant treatment effect when there is
in fact such effect exists. When this is the case,
conclusion made based on a single study is obviously
invalid, thus combined data from multiple but
comparable studies are considered.15
Similar scenario would have happened even if
conclusion is made based on combined studies but
merelyaccording toreviewer’sviewwithoutsystematic
approach in literature identification and quality
assessment of information. Back in 1981, an article
by J.R. Mitchell published in BMJ reviewed over the
previous 20 years clinical trials on the use of beta-
blocker in patients surviving from myocardial
infarction.16 This reviewsuggested that there isno clear
evidence if the use of beta-blocker may improve the
long-term survival of post myocardial infarction
patients.16 In contrast, another review article by J.R.
Hampton published in European Heart Journal within
the same year and came up with opposite conclusion.17
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“For the moment it seems perfectly reasonable to
treat patients who have survived an infarction for
two or three weeks with timolol,…”
Despite its observation over the previous clinical
trials, ifcautiousattentionispaid to thesereviewarticles,
there was no statement as to how these authors
conducted literature search, or how these authors
assessedthemethodologicalqualityofreviewedstudies.
In light of this, an article by Mulrow reported that
during mid 1980s,18 only one of 50 published reviews
in leading general medicine journals clearly specified
methods of identifying, selecting, and perform the
standardizedmethodologicalqualityassessmentof their
reviewed articles. Therefore, it is not surprising that
the two articles as illustrated above would have had
such an opposite conclusive statement. Importantly, it
also seems conceivable that without formal guidelines,
reviewers would only pick whatever relevant articles
stored in their filling cabinet to be reviewed and
potentially ignore the significant contribution of other
“un-reviewed” article in generating conclusion.
Principals and methods in conducting a systematic
review
To obtain adequate power to detect a treatment
effect, instead of having to recruit 10,000 participants,
investigator might think to include 10 existing
comparable studies of 1,000 participants, which is
perhapsmore feasible. Systematic reviewis essentially
a study of studies, with a single study being considered
as a participant.19,20 A systematic review without a
statistical combination of data, but merely a general
summary,maybecalledqualitativesystematic review.21
On the other hand, a systematic review that uses
statistical methods to quantitatively combine data and
generate summary is called quantitative systematic
review or meta-analysis.22 Therefore, having treated a
study likesingleparticipants in a single study, the result
of systematic review may be violated by including
irrelevant studies or excluding relevant studies, or
inappropriate statistical methods for the meta-analysis,
ifany.Thisviolationorbiascanbereducedbyfollowing
several basic principles and standardized methods in
performing systematic review, which are very similar
to a single study.
Developing research question, protocols, and
inclusion/exclusion criteria
Conducting a systematic review should be based
onrelevantandapplicableresearchquestion.Acriterion
to formulate good and representative research question
has been proposed previously and widely used to date,
following the PICO model23:
a) Patient, population, or problem (P): covering
the target population or patients, age, or par-
ticular clinical condition;
b) Intervention (I): covering intervention or expo-
sure, or any form of treatment, diagnostic test
which will be applied to the target population;
c) Control or comparison intervention (C): this is
only applied for studies with control group; and
d) Outcomes or expected effect (O): expected
outcomes from the proposed study.
An example of well-defined research question,
from the systematic review by Lago et al.24 is: Is
patients with pre-diabetes or diabetes (P) given
thiazolidinediones (I) versus placebo or no treatment
(C) have higher risk of congestive heart failure and of
cardiac death (O)? In addition, few other approaches
to define research question are also available.25
Oncethestudyquestionhasbeenwell-formulated,
clear and detailed objectives and protocol should be
written in advanced. This may include the subgroup
of interest, and detailed methods on how investigator
will identify and select relevant studies, inclusion and
exclusion criteria of studies to be included in the
analysis, and how to extract and analyze information
from included studies. The importance of having such
pre-defined protocol is to avoid bias introduced by
additional analysis driven by unexpected data.21,22,26,27
It is also highly recommended that investigator have a
clear check-list form containing all items specified in
this protocol.21
METHODS FOR LITERATURE SEARCH
The easiest way to distinguish systematic review
and traditional review is by following the methods for
literature identification.18, 20,28 In traditional review,
authors rarely mention how they perform the literature
search, thus it is almost impossible to replicate. On the
contrary, in systematic review, strategies for literature
search need to be clearly stated, including the
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keywords, databases, conference proceedings, or even
traditional mail to relevant author if any inclusion of
unpublished paper was used in the review. It is very
important to ensure that the literature search method
is replicable and repeatable. Several works have
identified themost efficient and highly sensitive search
strategy forclinical trialsand prognostic and diagnostic
studies.29 However, in many cases, a search term based
on thePICOdescription isadequate to identify relevant
articles to be included in the review.30
Several large medical-related databases have
included tens of thousands of literature, including
MEDLINE,31 EMBASE, the Cochrane Central
Register of Controlled Trial (CENTRAL, through the
Cochrane Library), or clinical trial registry. However,
other specialized databases such as Allied and
Alternative Medicine (AMED), BiologicalAbstracts
(BIOSIS), CAB Health, Cumulative Index to Nursing
and Allied Health Literature (CINAHL), conference
proceedings, and bibliographies of review articles,
monographs studies, hand-searching of key
publications, or even unpublished studies are also
essential since their result may be systematically
different from published studies.22
Selection and critical appraisal of methodological
quality of studies
A large number of quality assessment methods
and quality scales havebeen published.21,32-36 Yet, there
is no universal consensus on which criteria should
investigator follows. The quality assessment might
cover the design of trial, conduct and analysis,
applicability, and also the quality of reporting,37 but
importantly, these aspects should be early mentioned
in the protocol.22 In general, an key element of study
quality is determined by the question “how valid is the
result generated by a study?”, which relates to internal
validity, carefuldesign, conduct, andanalysisofastudy
toprevent biased result, andexternal validity, theextent
to which the result can be applied to other
circumstances.38
Again, selecting and assessing potential studies
are somewhat subjective process. Therefore it is of
importance to have more than one observer checking
theeligibilityofpotentialstudiesandassessingthequality
of those studies following exactly similar protocol. It is
alsobeneficial tohaveassessorsblindedfromthenames
of the authors and their institution, names of journals,
sources of funding, and acknowledgment to avoid bias
due to subjective preferences. Furthermore, all of this
selection and assessment procedures need to be
recorded in a standardized record form.
Data extraction and analysis
In extracting the data of selected studies, it is also
important to record the extraction steps in a pre-
specified data extraction form and involve more than
one observer to eliminate the possibility of different
interpretation.Acomprehensive overview of extracted
data should be presented clearly in the result section
of the systematic review.39, 40 Once the data have been
extracted, in one hand, it is relatively straightforward
to generate the conclusion either qualitatively or
quantitatively if selected studies are comparable and
similar.On theotherhand, if thedataarenot sufficiently
similar,aquantitativesummarywithparticularstatistical
methods need to be performed to address this
heterogeneity, called meta-analysis.12,26,33
Detailed discussion on this method is beyond the
scope of this review. Briefly, meta-analysis estimates
the pooled summary of effects observed in different
studies.41 This statistical pooling is based on the fixed-
variance of each study (fixed effect), in which studies
with larger sample size and number of events have
more influence in the pooled summary, or based on
the randomly distributed true treatment effect between
studies (random effect).42,43 There are several available
software to perform meta-analysis such as Review
Manager (RevMan) (available for free from the
CochraneLibrary),MetaWin(http://www.metawinsoft.
com), DSTAT (http://www.erlbaum.com), or also
available from general statistical packages such as
STATA (http://www.stata.com), SAS (http://




Conclusion is made based on the results of data
analysis, and recommendation for future research can
be constructed when available data are still insufficient
or their quality is not adequate. However, this is not as
easy as it seems to be. It is such ashamed that after
long effort to develop and write the review, the authors
only comesup withunsatisfactory conclusionand miss
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the opportunity to recognize interesting gaps which
remain unanswered in the review, which turns down
readers. For this reason, Brown and associates
proposed a recommendation to formulate research
conclusion and recommendation particularly for
systematic review.44 Their recommendation was to use
(E)vidence (P)opulation (I)ntervention (C)omparison
(O)utcome and (T)ime stamp or EPICOT formula,44
as the extension of PICO.
Systematic review: trustworthy?
Despite the potentials and promises of systematic
review, limitations should also be noted. There are
indeed systematic reviews addressing similar issues,
yet their conclusions are opposite.45,46 For example,
there were two systematic reviews assessing the use
of low-molecular-weight heparin for the prevention of
post surgical thrombosis compared to standard
heparin.45,46 The first review by Nurmohamed et al.46
suggested that there was no evidence that low
molecularweightheparin issuperior tostandardheparin
for preventing post surgical thrombosis. In contrast,
the other review by Leizorovich et al.45 reported that
lowmolecularweightheparinhadbeneficialeffectover
standardheparin inpreventingthrombosis. Interestingly,
not only were published within the same year, 1992,
by two of the most major medical journal, Lancet and
BMJ, these two reviews also mentioned that they
included publications within the same period, 1984 to
1991. Nevertheless, this contradictory conclusion may
have arisen because the first review did not include
unpublished data and had language restriction in
searching the literature, while the second review,
althoughincludedunpublisheddataandhadnolanguage
restriction, itdidnotassess thequality of included trials.
If readers were given these two reviews, which one
should they choose?
Evidently, the conclusion of systematic review
may be very solid or otherwise flawed depending on
the quality of selected studies. If the “raw” materials
are of low-quality, the conclusion generated by such
review would also be highly questionable. Studies
included in the systematic reviews need to be of high
methodological quality, within which observed
difference between treatment and control groups is
confidently a result of the intervention effect, but not
driven by selection bias (differences in baseline criteria
between treatment and control group), performance
bias (unequal provision of care between treatment and
control group), decision bias (bias on assessment), or
attrition bias (bias due to exclusion of patients after
allocation to treatment groups).38 There are studies
showing the impact of these biases on the ultimate
results of clinical trials. For example, Schulz et al.47
demonstrated that trials in which participants were
aware of their treatment allocation had 30 – 40% larger
effectscompared to trialswithappropriateconcealment
of treatment allocation.
In addition to quality assessment of included trial,
thorough identification of all relevant studies is also a
key to successful systematic reviews. How important
it is to include such unpublished data?Astudy by Stern
and Simes48 showed that among 321 studies included
in this study, only 25% of those with non-significant
result were published within 10 years, whereas almost
all of studies with significant results were published
within 10 years. Similarly, this report also showed that
the median time for studies with significant results to
be published was less than 5 years, while those with
non-significant results took 8 years to be published.48
These findings indicatepublicationand time lag biases,
in which studies with positive results are more likely to
be published and mostly dominate the literature for
years until those with negative results, but just as
important, finally get published.49,50 Therefore,
publication bias and time lag bias are very important
issue and exclusion of unpublished data will cause
ignorance of any important findings.51,52
Another most common source of bias in
systematic reviewis languagebias. It isnoted that most
of“prestigious”journalsarepublishedinEnglish;hence,
most investigatorsareencouragedtopublishtheir results
in English. However, does this mean that good quality
studies are always published in English? Or is it
representativeenoughtoonlyincludeEnglish-published
studies in systematic review?
Many systematic reviews are restricted their
inclusion to includeonly English literature.53 However,
investigators from non-English native countries may
also consider publishing some of their works in local
journal.29 Importantly, there are possibilities that
significant results or higher quality studies are likely to
bepublishedinEnglish-languagejournal,whilekeeping
the non-significant/ lower quality ones for local
journals.54Areport fromtheGerman literatureby Egger
and associates suggested that more than 60% of trials
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with non-significant results were published in German
as compared to only about 40% were published in
English.55 Similarly, there is also evidence that non-
English trials are of lower methodological quality.54
Therefore, bias could be introduced in systematic
reviews in which only include English literature.
CONCLUSION
Systematic review has acquired substantial
attention particularly among clinicians. This technique
was initially developed to summarize results from
different studies within the similar problems, and it
may be applied even for small studies with sizeable
variations. Performing systematic review therefore
requires expertise in both method and the context, and
very often demands collaboration between clinicians,
epidemiologist, and statistician. The question must be
clearly defined to maximize the relevance of included
studies. Investigators must then search for every
relevant study from multiple databases, reviewing
bibliographies, and seeking widely for unpublished
work. The collected reports then must also be carefully
selected and critically appraised to meet the relevance
and requirements of the systematic review, thus the
main information can be abstracted in the review to
answer the question.
It is increasingly clear that the essential recipe for
high-quality systematic review should include the fine
quality of included studies, comprehensive literature
search, and abstracting key information from research
reports, not merely a summary. Nevertheless, there
arestill many published systematic reviewwitha range
of serious problems which make is hard to trust the
conclusion, including the failure of investigator to
perform the literature search or critical appraisal,
careless in abstracting and summarize the selected
reports, and perhaps the most often, overstatement of
the strength of the conclusion. Moreover, it is also not
surprising to find that two or more systematic review
done at the same time without compatible conclusion.
These varieties of problems clearly argue against the
notion that systematic review may offer “the highest
level of scientific evidence” for clinical decision. On
the other hand, it powerfully suggests that quality of
systematic review remains needing thorough
assessment;otherwisepotentially jeopardize theclinical
decision.
In the author’s perspectives, systematic review
can help, but should never replace, strong clinical
reasoning about individual patient on the basis of
analogy,physician’sexperience,clinical investigations,
fundamental medical theory and knowledge, as well
as researched evidence.56-58 Awareness of treatment
effectiveness derived from the systematic review is
evidenceorknowledge, thuswouldnotgivephysicians
the clinical skills about how to use that treatment in
treating patients, which can be obtained from clinical
training and years of practicing experience. It will lead
toabaddecision ifapplied inanuncriticalandunfeeling
way.57 Therefore, the complexity of clinical decision
making can never be replaced by a single document of
compiled reports, because it is a state-of-the-art in
which knowledge, skills, value and research evidence
are integrated in every case by case scenario.
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